Growing list of Treg start-ups — who, what and how much more: Data Byte

In announcing nine-figure raises, GentiBio and Sonoma have each revealed more details about their platform technologies, highlighting a major fault line dividing the field.

On Wednesday, GentiBio Inc. said it raised a $157 million series A round in support of its build-a-Treg approach to the immunosuppressive cell therapy, which involves engineering a broad swath of CD4⁺ T cells to express the Treg master regulator FOXP3. The company is using synthetic receptors to fuel the cells with artificial IL-2 signaling, and keeping optionality between TCR and CAR-based tissue targeting strategies; its lead program, for Type I diabetes, will begin IND-enabling studies before year-end...